Related Experiment Video

Updated: Jul 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma

Wenjun Wang1, Howard D Edington, Drazen M Jukic

  • 1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Hillman Cancer Center, Research Pavilion, Suite 1.32, 5117 Centre Avenue, Pittsburgh, PA 15213-2584, USA.

Cancer Immunology, Immunotherapy : CII
|April 4, 2008
PubMed
Abstract

Insights

High-dose IFNalpha2b (HDI) down-regulates STAT3 and MAPK signaling in melanoma patients. This adjuvant therapy impacts tumor cells differently than lymphoid cells, revealing new insights into melanoma treatment mechanisms.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • High-dose IFNalpha2b (HDI) is an established adjuvant therapy for resected melanoma.
  • The molecular mechanisms underlying HDI's efficacy remain incompletely understood.
  • Signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinases (MAPKs) are implicated in melanoma progression and immune response.

Purpose of the Study:

  • To investigate the effects of neoadjuvant HDI on STAT3 and MEK/ERK MAPK signaling pathways in patients with stage IIIB melanoma.
  • To elucidate the molecular mechanisms of HDI in the context of a neoadjuvant therapeutic approach.

Main Methods:

  • Prospective neoadjuvant trial (UPCI 00-008) involving daily HDI administration for 20 doses prior to surgery.
  • Immunohistochemistry was performed on paired tumor biopsies to assess levels of pSTAT3, phospho-MEK1/2, phospho-ERK1/2, and EGFR.

Main Results:

  • HDI significantly down-regulated pSTAT3 and phospho-MEK1/2 levels in melanoma tumor cells (P = 0.008).
  • Phospho-ERK1/2 was also down-regulated in tumor cells (P = 0.015) but not in lymphoid cells.
  • HDI treatment led to down-regulation of EGFR (P = 0.013), with STAT3 activation appearing independent of EGFR and the MEK/ERK pathway.

Conclusions:

  • HDI differentially regulates MAPK signaling in melanoma tumor cells versus host lymphoid cells in vivo.
  • STAT3 activation in this context is independent of the EGFR/MEK/ERK signaling pathway.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...